SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (1796)10/22/2007 6:44:50 AM
From: Icebrg  Read Replies (1) | Respond to of 1826
 
MGI Pharma "outperform," target price raised

Friday, October 19, 2007 5:28:18 AM ET
BMO Capital Markets

NEW YORK, October 19 (newratings.com) - In a research note published yesterday, analysts at BMO Capital Markets reiterate their "outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price has been raised from $33 to $38.